Dermata Therapeutics Inc (DRMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has a cash flow conversion efficiency ratio of -0.214x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.33 Million) by net assets ($6.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dermata Therapeutics Inc (DRMA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Dermata Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dermata Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermata Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TENET FINTECH GROUP INC.
F:P0T
|
-17.433x |
|
Colipays Reunion SA
PA:MLCLP
|
N/A |
|
Tarena International Inc
NASDAQ:TCTM
|
N/A |
|
Questor Technology Inc.
V:QST
|
-0.015x |
|
Fabric.AI, Inc.
NASDAQ:FABC
|
-0.170x |
|
LUPAKA GOLD CORP.
F:LQPA
|
0.173x |
|
Transcode Therapeutics Inc
NASDAQ:RNAZ
|
-0.788x |
|
Akash Infra-Projects Limited
NSE:AKASH
|
0.021x |
Annual Cash Flow Conversion Efficiency for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see DRMA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.22 Billion | $-7.76 Billion | -1.247x | +82.57% |
| 2024-12-31 | $1.56 Million | $-11.16 Million | -7.151x | -609.06% |
| 2023-12-31 | $6.36 Million | $-6.41 Million | -1.008x | +31.26% |
| 2022-12-31 | $6.02 Million | $-8.83 Million | -1.467x | -160.43% |
| 2021-12-31 | $10.11 Million | $-5.69 Million | -0.563x | -144.44% |
| 2020-12-31 | $-3.18 Million | $-4.03 Million | 1.268x | -93.21% |
| 2019-12-31 | $-210.16K | $-3.92 Million | 18.663x | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more